Novavax Initiates Australian Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza-- First participants enrolled in Phase 1 clinical trial of combination NanoFlu™/NVX-CoV2373 vaccine with Matrix-M™ adjuvant-- Phase 1/2 study will evaluate immunogenicity and safety
GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate the safety and immunogenicity of a combination vaccine using Novavax' seasonal influenza and COVID-19 vaccines. The clinical trial combines Novavax' recombinant protein-based NVX-CoV2373 and NanoFlu™ vaccine candidates and patented saponin-based Matrix-M™ adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine). Both NVX-CoV2373 and NanoFlu have previously demonstrated strong results as standalone vaccines in Phase 3 clinical trials.
"This study is the first-of-its-kind to evaluate the vaccine's potential to induce a robust immune response, augmented by our Matrix-M adjuvant, against two life-threatening diseases simultaneously," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "The combination of these two vaccines, which have individually delivered outstanding results with favorable safety and tolerability profiles, may lead to greater efficiencies for the healthcare system and achieve high levels of protection against COVID-19 and influenza with a single regimen."
The trial will evaluate the safety, tolerability and immune response to NanoFlu formulated together with NVX-CoV2373 and Matrix-M adjuvant in 640 healthy adults 50 to 70 years of age. Participants will have been either previously infected with the SARS-CoV-2 virus that causes COVID-19 or vaccinated through an authorized vaccine at least eight weeks prior to enrollment. All participants will be randomly assigned to cohorts to evaluate multiple formulations and will be dosed on Day 0 and again at Day 56. The trial will be conducted in Australia at up to 12 study sites, with results expected during the first half of 2022.
- Forums
- ASX - By Stock
- IDT
- Novavax and IDT Partnership
Novavax and IDT Partnership, page-58
-
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IDT (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $53.73M |
Open | High | Low | Value | Volume |
12.5¢ | 12.8¢ | 12.5¢ | $18.81K | 150.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 85680 | 12.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 338664 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 85680 | 0.125 |
5 | 308999 | 0.120 |
8 | 785476 | 0.115 |
8 | 438201 | 0.110 |
3 | 409533 | 0.105 |
Price($) | Vol. | No. |
---|---|---|
0.130 | 338664 | 3 |
0.135 | 60641 | 3 |
0.140 | 90000 | 3 |
0.145 | 114987 | 3 |
0.150 | 290870 | 5 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
IDT (ASX) Chart |